These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15078193)

  • 1. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.
    Elbekai RH; Korashy HM; El-Kadi AO
    Curr Drug Metab; 2004 Apr; 5(2):157-67. PubMed ID: 15078193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis.
    George J; Liddle C; Murray M; Byth K; Farrell GC
    Biochem Pharmacol; 1995 Mar; 49(7):873-81. PubMed ID: 7741759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.
    Forrester LM; Henderson CJ; Glancey MJ; Back DJ; Park BK; Ball SE; Kitteringham NR; McLaren AW; Miles JS; Skett P
    Biochem J; 1992 Jan; 281 ( Pt 2)(Pt 2):359-68. PubMed ID: 1736885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the effects of musk ketone on mouse hepatic cytochrome P450 enzymes.
    Stuard SB; Caudill D; Lehman-McKeeman LD
    Fundam Appl Toxicol; 1997 Dec; 40(2):264-71. PubMed ID: 9441723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postnatal development of hepatic oxidative, hydrolytic and conjugative drug-metabolizing enzymes in female horses.
    Nebbia C; Dacasto M; Carletti M
    Life Sci; 2004 Feb; 74(13):1605-19. PubMed ID: 14738905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis.
    Bastien MC; Leblond F; Pichette V; Villeneuve JP
    Can J Physiol Pharmacol; 2000 Nov; 78(11):912-9. PubMed ID: 11100940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of drug metabolizing enzymes in human liver cell line Hep G2.
    Dawson JR; Adams DJ; Wolf CR
    FEBS Lett; 1985 Apr; 183(2):219-22. PubMed ID: 3921402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective induction of phase II drug metabolizing enzyme activities by quinolines and isoquinolines.
    Le HT; Franklin MR
    Chem Biol Interact; 1997 Mar; 103(3):167-78. PubMed ID: 9134007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of constitutive and induced alkoxyresorufin O-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster liver microsomes.
    Weaver RJ; Thompson S; Smith G; Dickins M; Elcombe CR; Mayer RT; Burke MD
    Biochem Pharmacol; 1994 Mar; 47(5):763-73. PubMed ID: 8135852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
    Johnson TN; Boussery K; Rowland-Yeo K; Tucker GT; Rostami-Hodjegan A
    Clin Pharmacokinet; 2010 Mar; 49(3):189-206. PubMed ID: 20170207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction and inhibition of mouse cytochrome P-450 2B enzymes by musk xylene.
    Lehman-McKeeman LD; Johnson DR; Caudill D
    Toxicol Appl Pharmacol; 1997 Jan; 142(1):169-77. PubMed ID: 9007046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver injury and expression of cytochromes P450: evidence that regulation of CYP2A5 is different from that of other major xenobiotic metabolizing CYP enzymes.
    Camus-Randon AM; Raffalli F; Béréziat JC; McGregor D; Konstandi M; Lang MA
    Toxicol Appl Pharmacol; 1996 May; 138(1):140-8. PubMed ID: 8658503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
    Rushmore TH; Kong AN
    Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly.
    Wauthier V; Verbeeck RK; Calderon PB
    Curr Med Chem; 2007; 14(7):745-57. PubMed ID: 17346160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction and inhibition of cytochrome P450 isoforms by imazalil, a food contaminant, in mouse small intestine and liver.
    Muto N; Hirai H; Tanaka T; Itoh N; Tanaka K
    Xenobiotica; 1997 Dec; 27(12):1215-23. PubMed ID: 9460227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fipronil induces CYP isoforms in rats.
    Caballero MV; Ares I; Martínez M; Martínez-Larrañaga MR; Anadón A; Martínez MA
    Food Chem Toxicol; 2015 Sep; 83():215-21. PubMed ID: 26142839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of some hypoglycemic herbs on the activity of phase I and II drug-metabolizing enzymes in alloxan-induced diabetic rats.
    Sheweita SA; Newairy AA; Mansour HA; Yousef MI
    Toxicology; 2002 May; 174(2):131-9. PubMed ID: 11985890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease.
    Velenosi TJ; Fu AY; Luo S; Wang H; Urquhart BL
    Drug Metab Dispos; 2012 Aug; 40(8):1508-14. PubMed ID: 22573661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis.
    Kirby GM; Batist G; Alpert L; Lamoureux E; Cameron RG; Alaoui-Jamali MA
    Toxicol Pathol; 1996; 24(4):458-67. PubMed ID: 8864187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.